Form 4: Glycomimetics Director and 10% Owner Fairmount Funds Reports Acquisition of Stock Options

Fairmount Funds Management LLC, a 10% owner and director of Glycomimetics Inc., reported the acquisition of 9,023 stock options with an exercise price of $15.30, vesting by June 2026.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Evan Harwin, all identified as Directors and 10% Owners of Glycomimetics Inc. (CBIO), reported the acquisition of stock options.
• The transaction involved the acquisition of 9,023 stock options with an exercise price of $15.30 per share.
• These options were acquired on June 23, 2025, and have an expiration date of June 23, 2035.
• The options vest in full on the earlier of June 23, 2026, or the date of the Issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.
• Peter Harwin holds these options for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to turn over any net cash or shares received to Fairmount for the benefit of such Fairmount Fund.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. are deemed directors by deputization due to Peter Harwin's service on the board of directors of Glycomimetics Inc. and his role as a manager of Fairmount.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (option grant) to a director and significant shareholder, which generally aligns interests. It is a neutral to slightly positive event as it incentivizes long-term commitment, but does not indicate new operational or financial performance.

Positives

• The grant of stock options to a director and significant shareholder aligns their interests with those of other shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the reporting person to the company's success.

Risks

• The options are subject to vesting conditions, specifically the Reporting Person's continued service to the Issuer, meaning the options may not fully vest if service ceases.
• The value of the options is dependent on the future market price of Glycomimetics Inc. ordinary shares exceeding the exercise price of $15.30; if the share price remains below this, the options may expire worthless.

Future Outlook

The vesting schedule for the acquired stock options indicates an expectation of continued service from the reporting person to Glycomimetics Inc. until at least June 23, 2026, or the next annual meeting.

Management Comments

• Peter Harwin holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to turn over to Fairmount any net cash or shares received from the option for the benefit of such Fairmount Fund.
• Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
• Fairmount and Fairmount Healthcare Fund II LP may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.

Industry Context

The grant of stock options to directors and significant shareholders is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation designed to align management and investor interests with company performance.

Comparison to Industry Standards

• Granting stock options to directors and key personnel is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize performance and retention.
• The specific number of options (9,023) and the exercise price ($15.30) would typically be evaluated against the company's overall compensation philosophy, market capitalization, and peer group compensation benchmarks, though this document alone does not provide sufficient detail for such a granular comparison.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Peter Harwin, a director and representative of a 10% owner (Fairmount Funds Management LLC), constitutes a related party transaction as it involves compensation from the Issuer to an affiliated party.

Stakeholder Impact

• Shareholders: The option grant aligns the interests of a significant shareholder and director with other shareholders, potentially leading to more focused efforts on increasing shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The vesting conditions incentivize continued service and performance from the director.

Next Steps

• The stock options will vest in full on the earlier of June 23, 2026, or the date of Glycomimetics Inc.'s next annual meeting of shareholders, subject to continued service.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Stock Options, Glycomimetics Inc., CBIO, Fairmount Funds Management, Director Compensation, Beneficial Ownership, Equity Grant, Vesting